0.1000USD-28.57%Mkt Cap: 485187 USDP/E: —Last update: 2026-05-22
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap485.19K USD
Enterprise Value-945.23K USD
Revenue (TTM)389.78K USD
Gross Profit-3.08M USD
Net Income (TTM)-5.02M USD
Revenue/Share0.1280 USD
Last Price0.1000 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG—
EV/EBITDA0.17
EV/Revenue-2.43
P/S1.66
P/B0.43
EPS (TTM)-2.26
EPS (Forward)-3.20
52W Range
0.02003% of range3.170
52W High3.170 USD
52W Low0.0200 USD
Profitability
Gross Margin-573.65%
Oper. Margin-1387.94%
EBITDA Margin0.00%
Profit Margin-935.25%
ROE-261.34%
ROA-187.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.95M USD
CapEx (TTM)—
FCF Margin-725.32%
FCF Yield-582.70%
Net Debt-1.59M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.02
Current Ratio3.24
Quick Ratio2.89
Book Value/Sh0.3220 USD
Cash/Share0.4020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateNov 8, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.62M
Float4.33M
Insiders6.31%
Institutions1.30%
Short Interest
Short Ratio3.3d
Short % Float2.35%
Short % Out.2.24%
Shares Short100.09K
Short (prev mo.)133.45K
Technical
SMA 500.0724 (+38.1%)
SMA 2000.3106 (-67.8%)
Beta0.84
S&P 52W Chg28.31%
Avg Vol (30d)34.82K
Avg Vol (10d)45.95K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—